Skip to menu Skip to content Skip to footer
Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Overview

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Works

Search Professor Peter Mollee’s works on UQ eSpace

321 works between 1997 and 2025

181 - 200 of 321 works

2015

Conference Publication

Emergence of Fc gamma RIIb-dominance contributes to resistance to therapeutic antibodies in chronic lymphocytic leukemia patients

Burgess, Melinda, Gill, Devinder, Mapp, Sally, Ellis, Jonathan, Cheung, Catherine, Chambers, Lynne, Mattarollo, Stephen, Mollee, Peter and Saunders, Nicholas (2015). Emergence of Fc gamma RIIb-dominance contributes to resistance to therapeutic antibodies in chronic lymphocytic leukemia patients. XVI International Workshop on Chronic Lymphocytic Leukaemia 2015, Sydney, NSW, Australia, 6–9 September 2015. Abingdon, Oxfordshire, United Kingdom: Taylor & Francis.

Emergence of Fc gamma RIIb-dominance contributes to resistance to therapeutic antibodies in chronic lymphocytic leukemia patients

2014

Journal Article

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Benboubker, Lotfi, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John, Belch, Andrew R, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J, Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason ... Mollee, Peter (2014). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England Journal of Medicine, 371 (10), 906-17. doi: 10.1056/NEJMoa1402551

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

2014

Journal Article

Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients

Jackson, Kathryn, Kennedy, Glen, Mollee, Peter, Marlton, Paula and Morris, Kirk (2014). Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. Asia-Pacific Journal of Clinical Oncology, 10 (3), 246-254. doi: 10.1111/ajco.12188

Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients

2014

Journal Article

Successful treatment of iatrogenic multicentric castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient

Speicher, D. J., Sehu, M. M., Mollee, P., Shen, L., Johnson, N. W. and Faoagali, J. L. (2014). Successful treatment of iatrogenic multicentric castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient. American Journal of Transplantation, 14 (5), 1207-1213. doi: 10.1111/ajt.12693

Successful treatment of iatrogenic multicentric castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient

2014

Journal Article

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Tan, P., Wei, A., Mithraprabhu, S., Cummings, N., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., Mollee, P., Grigg, A., D'Andrea, R., Dear, A. and Spencer, A. (2014). Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer Journal, 4 (1) e170, e170-e170. doi: 10.1038/bcj.2013.68

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

2014

Journal Article

How to diagnose amyloidosis

Mollee, P., Renaut, P., Gottlieb, D. and Goodman, H. (2014). How to diagnose amyloidosis. Internal Medicine Journal, 44 (1), 7-17. doi: 10.1111/imj.12288

How to diagnose amyloidosis

2014

Conference Publication

New diagnostic strategies for assessment of amyloidosis and myeloma

Mollee, Peter (2014). New diagnostic strategies for assessment of amyloidosis and myeloma. 48th Annual Scientific Meeting of the Australasian Division of the IAP, Brisbane, QLD Australia, 31 May – 2 June 2024. Oxford, United Kingdom: Elsevier. doi: 10.1097/01.pat.0000443473.89668.b2

New diagnostic strategies for assessment of amyloidosis and myeloma

2014

Journal Article

Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry

Adams, Rebecca L. C., Cheung, Catherine, Banh, Raymond, Saal, Russell, Cross, Donna, Gill, Devinder, Self, Marlene, Klein, Kerenaftali and Mollee, Peter (2014). Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Cytometry Part B - Clinical Cytometry, 86 (2), 80-90. doi: 10.1002/cyto.b.21138

Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry

2014

Conference Publication

Recommendations for Serum Free Light Chains (Sflc) Measurement in Routine Laboratories

Tate, Jill, Jovanovich, Sue, Mollee, Peter, Chiu, Weldon, Wienholt, Louise, Gillis, David, Reibelt, Lindsay and Youdell, Odette (2014). Recommendations for Serum Free Light Chains (Sflc) Measurement in Routine Laboratories. Unknown, Unknown, Unknown. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia.

Recommendations for Serum Free Light Chains (Sflc) Measurement in Routine Laboratories

2013

Journal Article

Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis

Mollee, Peter, Tate, Jill and Pretorius, Carel J. (2013). Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clinical Chemistry and Laboratory Medicine, 51 (12), 2303-2310. doi: 10.1515/cclm-2013-0361

Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis

2013

Conference Publication

Rapid Molecular Diagnosis Of JAK2V617F Negative MPN By Targeted Deep Sequencing Using The Ion Torrent PGM

Klose, Nathan, Tallack, Michael R, Magor, Graham, Mollee, Peter and Perkins, Andrew C (2013). Rapid Molecular Diagnosis Of JAK2V617F Negative MPN By Targeted Deep Sequencing Using The Ion Torrent PGM. 55th ASH Annual Meeting, New Orleans, LA, 7-10 December 2013. American Society of Hematology. doi: 10.1182/blood.v122.21.4093.4093

Rapid Molecular Diagnosis Of JAK2V617F Negative MPN By Targeted Deep Sequencing Using The Ion Torrent PGM

2013

Conference Publication

Diagnosis of amyloidosis subtype by laser-capture microdissection (LCM) and tandem mass spectrometry (MS) proteomic analysis

Mollee, Peter, Renaut, Patricia, Boros, Samuel, Loo, Dorothy and Hill, Michelle (2013). Diagnosis of amyloidosis subtype by laser-capture microdissection (LCM) and tandem mass spectrometry (MS) proteomic analysis. 55th ASH Annual Meeting, New Orleans, LA United States, 7-10 December 2013. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v122.21.5295.5295

Diagnosis of amyloidosis subtype by laser-capture microdissection (LCM) and tandem mass spectrometry (MS) proteomic analysis

2013

Conference Publication

Diagnosis Of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS) Proteomic Analysis

Mollee, Peter, Renaut, Patricia, Boros, Samuel, Loo, Dorothy and Hill, Michelle (2013). Diagnosis Of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS) Proteomic Analysis. 55th Annual Meeting of the American-Society-of-Hematology, New Orleans La, Dec 07-10, 2013. WASHINGTON: AMER SOC HEMATOLOGY.

Diagnosis Of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS) Proteomic Analysis

2013

Conference Publication

Serum levels Of CD178 (Soluble FasL) predict treatment response and survival in chronic lymphocytic leukaemia (CLL)

Mollee, Peter, Burgess, Melinda, McMillan, Nigel, Saunders, Nicholas, Cheung, Catherine, Hallek, Michael and Gill, Devinder S (2013). Serum levels Of CD178 (Soluble FasL) predict treatment response and survival in chronic lymphocytic leukaemia (CLL). 55th ASH Annual Meeting, New Orleans, LA, 7-10 December 2013. American Society of Hematology. doi: 10.1182/blood.v122.21.2866.2866

Serum levels Of CD178 (Soluble FasL) predict treatment response and survival in chronic lymphocytic leukaemia (CLL)

2013

Journal Article

Towards improved measurement of serum free light chains: clinical and laboratory issues

Tate, Jill and Mollee, Peter (2013). Towards improved measurement of serum free light chains: clinical and laboratory issues. Biochimica Clinica, 37 (5), 395-404.

Towards improved measurement of serum free light chains: clinical and laboratory issues

2013

Journal Article

CD62L as a therapeutic target in chronic lymphocytic leukemia

Burgess, Melinda, Gill, Devinder, Singhania, Richa, Cheung, Catherine, Chambers, Lynne, Renyolds, Brent A., Smith, Louise, Mollee, Peter, Saunders, Nicholas and McMillan, Nigel A. J. (2013). CD62L as a therapeutic target in chronic lymphocytic leukemia. Clinical Cancer Research, 19 (20), 5675-5685. doi: 10.1158/1078-0432.CCR-13-1037

CD62L as a therapeutic target in chronic lymphocytic leukemia

2013

Journal Article

Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival

Jackson, K., Mollee, P., Morris, K. and Kennedy, G. (2013). Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival. Internal Medicine Journal, 43 (8), 953-954. doi: 10.1111/imj.12218

Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival

2013

Journal Article

Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital

Solano, Connie, Mutsando, Howard, Self, Marlene, Morel-Kopp, Marie-Christine and Mollee, Peter (2013). Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital. Blood Coagulation & Fibrinolysis, 24 (4), 365-370. doi: 10.1097/MBC.0b013e32835cc17e

Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital

2013

Journal Article

Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit

Jackson, Kathryn, Mollee, Peter, Morris, Kirk, Butler, Jason, Jackson, Dwane, Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen (2013). Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. Leukemia and Lymphoma, 55 (1), 97-104. doi: 10.3109/10428194.2013.796045

Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit

2013

Conference Publication

Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients

Taylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2013). Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. 55th Annual Meeting of the American Society of Hematology, New Orleans, LA United States, 7-10 December 2013. Washington, DC United States: American Society of Hematology.

Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients

Supervision

Availability

Associate Professor Peter Mollee is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au